Newsletter

Healthcare Stocks

Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting

Beats revenue ceiling, EBITDA nearly doubles guidance midpoint as Myriad carries the result The number that matters in Aroa Biosurgery's (ASX:ARX) FY26 preliminary result is not the revenue beat itself. It is the gap. Aroa guided to NZ$92 to NZ$100 million in revenue at constant currency and printed NZ$101 million on that basis, exceeding the…

ByCharlie YouldenApril 30, 2026

Shares In Dimerix (ASX:DXB) Fell 40% Today; Not About The Data, But About the Timing

Shares in Dimerix fell over 35% this morning and some may think the decline was irrational. After all, the announcement confirmed >90 per cent statistical power for its primary endpoint, reminded the market that its 2024 futility analysis showed the drug outperforming placebo, and reported no safety issues across seven IDMC reviews. On paper, that…

ByNick SundichApril 28, 2026

Percheron Therapeutics (ASX:PER): An Oncology Biotech That’s Growing Its Footprint

Percheron Therapeutics is not the kind of company that typically commands market attention at a A$6–7m valuation. Yet the more one looks at its trajectory over the past twelve months, the more it becomes clear that the market is missing something important. The company has moved from being a near‑dormant shell to a clinical‑stage immuno‑oncology…

ByNick SundichApril 28, 2026

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their cash as they have earned on their investments. We felt that it was time to write a stand-alone article about this in light of the inflation crisis and how it could lead to investors seeking…

ByNick SundichApril 28, 2026

Medical Developments (ASX:MVP) Surges 35% After Penthrox Drives Positive Cash Flow and European Expansion

Medical Developments International (ASX:MVP) jumped 35% on Friday to close at A$0.52 after a Q3 FY26 update that surprised the market on two fronts. The company delivered positive operating cash flow, and Pain Management revenue jumped 47% year-on-year to A$8.4 million. For a small-cap that has spent years burning cash, this looks like a genuine…

ByUjjwal MaheshwariApril 27, 2026

ASX Healthcare Sector Sheds 6% in a Day: 3 Stocks Now Trading at Bargain Levels

The ASX healthcare sector lost 6% in a single day on Wednesday, its worst session in years. The trigger was Cochlear (ASX:COH), which fell 40.7% to a decade-low of A$99.58 after slashing its profit guidance. The damage spread well beyond Cochlear itself, with CSL (ASX:CSL) down 5.7%, ResMed (ASX:RMD) off 2.5%, and most other healthcare…

ByUjjwal MaheshwariApril 23, 2026

Shares In Cochlear (ASX:COH) Plunge Over 35% As FY26 Guidance Is Slashed By Nearly A Third! Is It A Buy The Dip Opportunity?

If you own shares in Cochlear (ASX:COH), you had a pretty bad morning. The company delivered one of the most significant earnings guidance downgrades in its listed history this morning, cutting its FY26 underlying net profit guidance to A$290–330m from a previously disclosed range of A$435–460m. The revision (a reduction of roughly 30% at the…

ByNick SundichApril 22, 2026

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off. Dimerix has been advancing DMX-200/Qytovra for several years DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…

ByNick SundichApril 21, 2026

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…

ByNick SundichApril 21, 2026

Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patts Bid: Shares Slide 6% on Second Knockback

Monash IVF Knockback Sends Shares Lower Monash IVF Group (ASX:MVF) shares slid nearly 6% to A$0.72 on Monday after the board rejected a revised A$0.90 per share takeover bid from a consortium led by Genesis Capital and Washington H. Soul Pattinson (ASX:SOL). This is the second rejection in five months, following the knockback of an…

ByUjjwal MaheshwariApril 21, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting

Shares In Dimerix (ASX:DXB) Fell 40% Today; Not About The Data, But About the Timing

Percheron Therapeutics (ASX:PER): An Oncology Biotech That’s Growing Its Footprint

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

Medical Developments (ASX:MVP) Surges 35% After Penthrox Drives Positive Cash Flow and European Expansion

ASX Healthcare Sector Sheds 6% in a Day: 3 Stocks Now Trading at Bargain Levels

Shares In Cochlear (ASX:COH) Plunge Over 35% As FY26 Guidance Is Slashed By Nearly A Third! Is It A Buy The Dip Opportunity?

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Monash IVF (ASX:MVF) Rejects A$0.90 Soul Patts Bid: Shares Slide 6% on Second Knockback

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here